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Newly developed or advanced methods of ultrasonography and
MR imaging provide combined anatomical and quantitative
functional information about diffuse and focal liver diseases.
Ultrasound elastography has a central role for staging liver
ﬁbrosis and an increasing role in grading portal hypertension;
dynamic contrast-enhanced ultrasonography may improve
tumor characterization. In clinical practice, MR imaging examin-
ations currently include diffusion-weighted and dynamic MR
imaging, enhanced with extracellular or hepatobiliary contrast
agents. Moreover, quantitative parameters obtained with
diffusion-weighted MR imaging, dynamic contrast-enhancedJournal of Hepatology 20
Keywords: Ultrasonography; Magnetic resonance imaging; Perfusion and
diffusion imaging; Dynamic gadoxetate-enhanced MR imaging; Elastography;
Imaging biomarkers; Liver diseases; Liver tumors.
Received 18 June 2014; received in revised form 8 October 2014; accepted 11 October
2014
⇑ Corresponding author. Address: Laboratory of Imaging Biomarkers and
Department of Radiology, Beaujon University Hospital, 100 Boulevard du General
Leclerc, 92110 Clichy, France. Tel.: +33 1 40 87 56 54; fax: +33 1 40 87 44 77.
E-mail address: bernard.van-beers@bjn.aphp.fr (B.E. Van Beers).
Abbreviations: AASLD, American Association for the Study of Liver Diseases; ADC,
apparent diffusion coefﬁcient; APRI, aspartate aminotransferase to platelets ratio
index; ARFI, acoustic radiation force imaging; AUROC, area under the receiver
operating curve; CT, computed tomography; D, pure diffusion coefﬁcient; D⁄,
perfusion-related diffusion coefﬁcient; DCE, dynamic contrast-enhanced; DW,
diffusion-weighted; EASL, European Association for the Study of the Liver;
EFSUMB, European Federation of Societies for Ultrasound in Medicine and
Biology; f, fraction of diffusion related to microcirculation; F, plasma ﬂow; G⁄,
shear wave modulus; Gd, storage modulus; Gl, loss modulus; HCC, hepatocellular
carcinoma; HCV, hepatitis C virus; IVIM, intravoxel incoherent motion; Ktrans,
transfer constant; K1a, arterial transfer constant; K1p, portal venous transfer
constant; K1t, total liver plasma transfer constant; MR, magnetic resonance; MRP,
multidrug resistance protein; MTT, mean transit time; NASH, non-alcoholic
steatohepatitis; OATP, organic anion transporting polypeptide; mRECIST,
modiﬁed response evaluation criteria in solid tumors; RECIST, response
evaluation criteria in solid tumors; STARD, standards for reporting diagnostic
accuracy; vd, distribution volume; ve, volume of extravascular extracellular space;
vp, plasma volume; WFUMB, World Federation for Ultrasound in Medicine and
Biology.MR imaging and MR elastography have the potential to charac-
terize further diffuse and focal liver diseases, by adding informa-
tion about tissue cellularity, perfusion, hepatocyte transport
function and visco-elasticity. The multiparametric capability of
ultrasonography and more markedly of MR imaging gives the
opportunity for high diagnostic performance by combining
imaging biomarkers. However, image acquisition and post-
processing methods should be further standardized and validated
in multicenter trials.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Liver ultrasonography and magnetic resonance (MR) imaging is
increasingly used for detecting, characterizing and assessing
the response to treatment of focal and diffuse liver diseases
[1–3]. Ultrasonography remains a ﬁrst-line examination, but
it has recently gained increasing capabilities due to the imple-
mentation of dynamic contrast-enhanced (DCE) studies and
elastography.
The quality and speed of MR imaging examinations have
been substantially improved by the development of higher
clinical ﬁeld strengths, larger gradients, improved surface coils,
and parallel imaging techniques [2]. Hepatobiliary contrast
agents, such as gadoxetate, have been introduced for DCE MR
imaging [4]. Relative to computed tomography (CT), MR imag-
ing has several advantages, including lack of radiation, higher
contrast-to-noise ratios, and multiparametric capabilities [1].
Indeed, the pulse sequences at MR imaging can be adjusted
to produce images that assess different tissue characteristics
such as diffusion, perfusion, and visco-elasticity [2,3]. These
functional characteristics can be assessed not only qualitatively,
but also as quantitative parameters that provide useful imaging
biomarkers [3].15 vol. 62 j 690–700
JOURNAL OF HEPATOLOGYKey Points
• Dynamic contrast-enhanced ultrasonography has the 
potential to give similar diagnostic performance for 
single liver tumour assessment as dynamic contrast-
enhanced MR imaging and can provide quantitative 
perfusion information
• Dynamic ultrasound elastography has a central role in 
liver fibrosis staging and is increasingly used to grade 
portal hypertension
• Acoustic radiation force ultrasound elastography 
measurements are fully integrated into comprehensive 
ultrasound examinations of the liver
• In patients with hepatocellular carcinoma, the 
quantitative MR diffusion and perfusion parameters, 
determined one month after intra-arterial or anti-
angiogenic treatments, have been shown to be better 
predictors of patient outcome than the RECIST, 
mRECIST or EASL criteria
• Dynamic gadoxetate-enhanced MR imaging improves 
the assessment of focal and diffuse liver diseases 
relative to dynamic contrast-enhanced imaging with 
extracellular contrast agents by adding information 
about hepatocyte transport function during the 
hepatobiliary phase
• Several visco-elastic parameters including the stiffness, 
elasticity, viscosity and wave scattering coefficients 
can be obtained in whole liver and spleen with 
multifrequency MR elastography, potentially improving 
the characterization of multiple liver diseases, including 
fibrosis, inflammation, NASH, portal hypertension, and 
liver tumours
• Biomarkers obtained with diffusion imaging, perfusion 
- hepatocyte transport imaging and with elastography 
have to be further validated in multicentre studies and 
the methods of image acquisition and post-processing 
have to be standardized
• Given the multiparametric capabilities of MR imaging 
and ultrasonography, imaging biomarkers can be 
combined to further improve the detection and 
characterization of diffuse liver diseases and liver 
tumours and to assess their response to treatment
UltrasonographyDynamic contrast-enhanced ultrasonography
Method
Dynamic contrast-enhanced ultrasonography is performed after
intravenous injection of ultrasound contrast agents. Ultrasound
contrast agents are blood agents that are composed of gas-ﬁlled
microbubbles stabilized by a shell made of lipids, proteins or
polymers. Because of the non-linear oscillation of the microbub-
bles at low to mid-high mechanical index, harmonic or non-linear
imaging is used to increase the contrast-to-tissue-ratio relative to
fundamental B-mode imaging [5].Journal of Hepatology 201Liver tumors
Dynamic contrast-enhanced ultrasonography improves the
detection and characterization of focal liver lesions [5]. Technical
and diagnostic guidelines for the detection, characterization, and
treatment monitoring of liver lesions at contrast-enhanced ultra-
sonography have been published under the auspice of the World
Federation for Ultrasound in Medicine and Biology (WFUMB) and
the European Federation of Societies for Ultrasound in Medicine
and Biology (EFSUMB) [6].
However, the diagnostic role of DCE ultrasonography relative
to DCE-CT and MR imaging remains debated [7]. Besides DCE-CT
and MR imaging, DCE ultrasonography was included in the diag-
nostic algorithm for suspected hepatocellular carcinoma (HCC) in
liver cirrhosis in the 2005 recommendations of the American
Association for the Study of Liver Diseases (AASLD) [8] and in
the recommendations of the Japan society of hepatology [9];
however, it was not included in the recent updated versions of
either AASLD or European Association for the Study of the Liver
(EASL) guidelines [10,11]. Reasons for this change have been
based on the fact that the typical hypervascularity and washout
pattern of HCC may be observed in some intrahepatic cholangio-
cellular carcinomas at DCE ultrasonography without being
observed at DCE MR imaging [12]. The different pattern observed
at ultrasonography and MR imaging or CT may be explained by
differences in the distribution volumes between the ultrasound
microbubbles, which remain intravascular, and the small-molec-
ular-weight CT and MR contrast materials, which instead distrib-
ute into the vascular and extravascular-extracellular spaces.
Other reasons for the variable use of DCE ultrasonography are
defect in standardization, dependence on the operator, variability
of results related to the physical characteristics of any individual
patient, and the lack in three-dimensional dynamic imaging [7].
In contrast, the real-time capability of DCE ultrasonography
may be a beneﬁt relative to CT and MR imaging for observing
the transient signal intensity enhancement of hypervascular liver
tumors such as HCCs [13].
A meta-analysis of sulphur hexaﬂuoride microbubble
enhanced ultrasonography reported that it could provide
improved cost-effectiveness and similar diagnostic performance
to DCE-CT and MR imaging for the assessment of focal liver
lesions [14]. However, the authors highlighted limitations in
the reporting of many studies of the review, and stressed the
need for further high-quality studies, based on the standards
for reporting diagnostic accuracy (STARD) criteria, which
compare the performance of all three imaging modalities (DCE
ultrasonography, CT, and MR imaging) in the same patients and
provide standardized deﬁnitions of a positive imaging test for
each target condition. Moreover, the effectiveness of DCE
ultrasonography in the assessment of multiple lesions of the liver
should also be considered [14].
Future perspectives in DCE ultrasonography include quantita-
tive perfusion imaging and molecular imaging [5,15]. The in vivo
feasibility of determining absolute tumor perfusion parameters at
DCE ultrasonography with deconvolution of the tumor enhance-
ment curve by the arterial input function has been shown [16].
In animal models, molecular imaging of angiogenesis and
inﬂammation has been performed with targeted ultrasound con-
trast agents directed to surface receptor molecules expressed on
the luminal side of activated endothelium, in response to either
inﬂammatory or angiogenic stimuli [5]. However, the unspeciﬁc5 vol. 62 j 690–700 691
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accumulation of microbubbles within Kupffer cells limits tar-
geted imaging approaches in liver diseases [17].Dynamic ultrasound elastography
Method
Dynamic elastography is based on the assessment of the propa-
gation of shear waves within tissues to calculate the visco-elastic
properties [18]. Displacements can be measured with ultrasonog-
raphy or MR imaging and stress can be applied either externally
or internally. In the former case, an external actuator is generally
directly in contact with the skin. The latter case includes methods
that apply a force internally, for example by using focused ultra-
sound pulses generating acoustic radiation force (ARF). Acoustic
pulses are used to ‘‘push’’ tissue, as well as capture the resulting
tissue motion [18].
External mechanical excitation may be either continuous or
transient. With ultrasonography, transient pulses are usually
used to avoid the problem of reﬂections caused by continuous
vibration.
Transient elastography (Fibroscan, Echosens, Paris, France)
is a ﬁrst-generation dynamic ultrasound elastography method.
It relies on the application of a short external shear wave pulse
that is tracked by using one-dimensional ultrasound imaging
[19]. Second generation ultrasound elastography methods are
based on ARF. ARF methods include acoustic radiation force
imaging (ARFI) (Siemens Healthcare, Erlangen, Germany),
supersonic shear imaging also called shear wave elastography
(Supersonic Imagine, Aix en Provence, France) and shear wave
dispersion ultrasound vibrometry (Philips Healthcare, Best, The
Netherlands) [20–22]. Quantitative ARFI estimates shear wave
speed by tracking the shear wave generated by the push at lateral
offsets from the push location, whereas supersonic shear imaging
uses ultrafast imaging at a frame rate up to 4000 frames per
second to assess the displacements resulting from the shear wave
propagation [18,23].
Because transient waves are usually used at ultrasound
elastography, only the wave speed can be calculated. This speed
is proportional to tissue stiffness or elasticity, if one assumes
that tissues are purely elastic. In fact, biological tissues are
visco-elastic because they are both liquid and solid. The visco-
elasticity can be assessed with ultrasound elastography by using
Voigt model ﬁtting of the frequency-dependent wave speed
dispersion [22]. However, the relevance of the Voigt model in
human tissues remains controversial [24].
With the ﬁrst generation transient elastography method,
shear wave speed is measured in a cylindrical volume 10-mm
wide, 40-mm long, located 25–65 mm below the skin surface.
The Fibroscan is an ultrasound apparatus that is dedicated for
assessing liver ﬁbrosis. No conventional B-mode ultrasound
image is available. The proper positioning of the elastography
box within the liver can thus not be assessed, nor can transient
elastography be performed in focal liver lesions.
Second generation ARF-based elastography methods have
advantages relative to transient elastography. First, the regions
of interest for elasticity measurements are overlaid on conven-
tional B mode images. Second, elastograms can be obtained in
patients with ascites when using ARF based methods, but not
with transient elastography. This is explained by the fact that
focused ultrasound beams in contrast to shear waves do
penetrate trough liquids. Third, as the shear waves are generated692 Journal of Hepatology 201internally with ARF methods, deeper regions of the liver can be
assessed. However, the deepest regions of the liver can be
difﬁcult to evaluate, as the depth limit for ARFI and shear wave
elastography has been reported to be 8 cm [25,26]. ARFI provides
a single estimate of tissue stiffness in a small region of tissue
(10  5 mm), whereas a whole elasticity map can be obtained
within a region of interest with shear wave elastography [26].
Diffuse liver diseases
Validation of dynamic elastography in liver diseases is ongoing.
For liver ﬁbrosis, transient elastography is currently the most
validated method for the assessment of liver ﬁbrosis, mainly in
viral hepatitis [27]. Its diagnostic accuracy is better for cirrhosis
than for signiﬁcant ﬁbrosis, with mean areas under the receiver
operating characteristic curves (AUROCs) of 0.94 and 0.84 in
patients with interpretable results [28]. The diagnostic accuracy
of transient elastography for signiﬁcant ﬁbrosis is not high
enough to recommend transient elastography as the sole exami-
nation in clinical practice [28–30]. Moreover, the main limitation
of transient elastography is its limited applicability: in about 20%
of the patients, examination fails or results are non-interpretable,
mostly because of obesity, ascites or limited operator experience
[31].
The accuracy of ARFI in liver ﬁbrosis is reported to be similar
to that of transient elastography, whereas a single center study
suggests that shear wave elastography is more accurate than
transient elastography for diagnosing signiﬁcant ﬁbrosis in HCV
patients [32,33]. Besides the staging of liver ﬁbrosis, ultrasound
elastography is emerging as an accurate method for staging
portal hypertension and detecting esophageal varices [34,35].
Liver tumors
Some studies have assessed the potential role of second genera-
tion ultrasound elastography in characterizing liver tumors
[25,26]. Despite the fact that signiﬁcant overlap of lesion stiffness
has been observed between benign and malignant lesions,
ultrasound elastography might be useful for more speciﬁc clinical
questions, such as the differentiation between adenoma and focal
nodular hyperplasia as well as between hepatocellular and
cholangiocellular carcinomas. Indeed, lesions of focal nodular
hyperplasia are stiffer than adenomas (Fig. 1), and cholangiocel-
lular carcinomas are stiffer than hepatocellular carcinomas
[25,26]. Moreover, higher stiffness is observed in inﬂammatory
than in steatotic adenomas [36].
Preliminary results suggest that combined DCE ultrasonogra-
phy and ultrasound elastography might be superior to each
method alone for characterizing liver tumors [37]. Tissue
biomechanical parameters may thus become additional useful
biomarkers to those obtained with Doppler and DCE ultrasonog-
raphy [38]. Further efforts on validation and standardization of
ultrasound elastography should be performed before the full
clinical impact of the method can be observed. Finally, one should
remind that multiple factors including hepatic ﬁbrosis, inﬂamma-
tion, cholestasis, congestion, steatosis and portal hypertension
can lead to overestimation of liver stiffness [39,40].
MR imaging
The role of MR imaging in assessing focal and diffuse liver dis-
eases has been reinforced these last years by the introduction
of quantitative imaging methods that add functional information5 vol. 62 j 690–700
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Fig. 1. Hepatic shearwave elastograms. (A) Patient with focal nodular hyper-
plasia and (B) patient with steatotic adenoma Higher stiffness (30.9 ± 1.7 kPa) is
observed in (A) focal nodular hyperplasia than (B) in adenoma (14.4 ± 1.7 kPa).
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Fig. 2. Higher robustness of breathhold acquisition of DW-MR imaging data
in calculating diffusion parameters. (A and C) Hepatic diffusion-weighted MR
images and (B and D) maps of perfusion fractions (%) in patients with metastases
(red contours) from colorectal cancer. Panels A and B are acquired during free
breathing, whereas C and D are acquired with breathholding in the same patient.
Black dots on B and D maps represent voxels with undetermined perfusion
fraction because of failure of least-square algorithm to calculate perfusion
fraction. More failures are observed on (B) free-breathing than (D) on corre-
sponding breathhold image, especially in metastasis of liver segment VI (short
arrow) and in upper pole of right kidney (long arrow). This ﬁgure illustrates the
higher robustness of breathhold acquisition of DW- MR imaging data in
calculating diffusion parameters.
JOURNAL OF HEPATOLOGYand can provide new imaging biomarkers. These methods include
diffusion-weighted (DW) MR imaging, DCE MR imaging and MR
elastography.
Diffusion-weighted MR imaging
Method
Diffusion-weighted MR imaging probes intracellular and extra-
cellular diffusion of water molecules by adding, in an echo-planar
MR imaging sequence, two diffusion gradients that decrease the
signal intensity according to tissue diffusibility and gradient
strength (b value). On high b-value MR images, the signal inten-
sity of lesions with high diffusibility such as cysts or hemangio-
mas will be nearly zero, whereas lesions with restricted
diffusion such as highly cellular malignant tumors will have
preserved high signal.
The decrease of signal intensity of tissues according to
increasing b-values is exponential, and the slope of this decrease
on a semi-logarithmic plot corresponds to the apparent diffusion
coefﬁcient (ADC). Additional diffusion parameters can be
assessed by probing signal intensity with multiple b-values.
Indeed, according to the intravoxel incoherent motion (IVIM)
model, signal intensity decrease on DW MR images at low b val-
ues (<100 s/mm2) is mainly caused by perfusion, whose speed is
much faster than that of extravascular diffusion [41,42]. There-
fore, at low b-values, the perfusion-related diffusion coefﬁcient
(D⁄) and the fraction of diffusion related to microcirculation
(f) can be calculated, whereas at high b-values the pure molecular
diffusion coefﬁcient (D) can be obtained.
The reproducibility and precision of the diffusion parameter
measurements in the liver are limited by macroscopic motion,
including respiratory and cardiac motion. Multiple methods haveJournal of Hepatology 201been proposed for motion compensation, including signal
averaging, respiratory triggering or tracking, breath-holding,
and cardiac triggering. However, the value of these methods
remains debated because they have drawbacks, including
increase in scan duration or decrease in signal-to-noise ratio [43].
The reproducibility of the diffusion parameters varies. High
reproducibility has been observed for ADC and D, the apparent
and true diffusion coefﬁcients, but lower reproducibility for f,
the fraction of diffusion related to microcirculation, and mainly
for D⁄, the perfusion-related diffusion coefﬁcient. The reported
repeatability coefﬁcients of ADC and D are 10–15% in the liver
and 25–30% in malignant liver tumors [44–46]. The reproducibil-
ity and robustness of the diffusion parameter measurements can
be improved by acquiring MR images during breath-holdings
(Fig. 2), increasing the number of b-values, and using Bayesian
analysis [47,48].
Liver tumors
Diffusion-weighted MR imaging is nowadays routinely per-
formed in patients with focal liver diseases. It can be used to
improve detection, characterization, and assessment of response
to treatment of liver tumors. DWMR imaging markedly improves
the detection of solid liver tumors relative to T2-weighted fast
spin-echo imaging, with lower to comparable accuracy compared
with DCE MR imaging [49–54]. Analyzing DW MR images with
DCE MR images improves the diagnostic performance relative
to the individual analysis of each imaging sequence.
Diffusion-weighted MR imaging is also useful for tumor char-
acterization. Malignant liver tumors have lower ADC than benign
lesions [55]. This is generally explained by the higher cellularity
in malignant tumors. In clinical practice, DW MR imaging criteria
have been deﬁned for characterizing benign and malignant
lesions based on the tumor-to-liver contrast. According to these
criteria, a lesion is considered benign if it appears hyperintense
on DW images with a b-value of 0 s/mm2, with a strong decrease5 vol. 62 j 690–700 693
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in signal intensity with a b-value of 500 s/mm2 or higher, and if
the lesion is hyperintense relative to the liver on the ADC map. A
lesion is considered malignant if the lesion is mildly to moder-
ately hyperintense on DW images with a b-value of 0 s/mm2
and remains hyperintense compared with liver parenchyma with
a b-value of 500 s/mm2 or higher, and if the lesion appears hyp-
ointense on the ADC map [50].
However, the characterization of liver tumors with ADC mea-
surements shows variable overlap between benign and malig-
nant lesions. Benign lesions with high ﬂuid content such as
liver cysts and hemangiomas clearly have higher ADC than
non-cystic malignant lesions, but the ADC of solid benign hepato-
cellular lesions such as focal nodular hyperplasia and adenoma
does not signiﬁcantly differ from that of solid malignant tumors
[56]. Therefore, the DW MR criteria for tumor characterization
are not useful for differentiating between benign hepatocellular
and malignant liver lesions in the normal liver.
One area where tumor characterization with DW MR imaging
appears useful is the characterization of nodules in cirrhosis.
Indeed, most HCC are hyperintense on DW MR images, whereas
dysplastic nodules rarely are [57]. It has been reported that lesion
hyperintensity on DW MR images is a more accurate sign of HCC
than delayed hypointensity on DCE MR images enhanced with
non-speciﬁc or hepatobiliary contrast agents [57–59]. The value
of the IVIM-derived parameters to characterize liver lesions has
been assessed in some studies. In a study of patients with 86 solid
liver tumors, Doblas et al. observed that the diffusion parameters
derived from the IVIM model did not improve the determination
of malignancy and characterization of hepatic tumor type, when
compared with the ADC [60]. In a series of 42 surgically con-
ﬁrmed HCC, Woo et al. observed a stronger degree of negative
correlation between the pure diffusion coefﬁcient D and tumor
grade than between ADC and grade. However, the accuracy of D
for differentiating between high- and low-grade HCC remained
modest because of substantial overlap in the results (AUROC:
0.84) [61].
Diffusion measurements may be useful to assess the tumor
response to treatment, by showing early diffusion parameter
changes related to necrosis [62]. It has been recently shown that
the volumetric ADC changes one month after intra-arterial treat-
ment of HCC showed stronger association with tumor response
than the size changes as assessed with the response evaluation
criteria in solid tumors (RECIST), the modiﬁed response evalua-
tion criteria in solid tumors (mRECIST) and the EASL criteria
[63,64]. These results are explained not only by the use of a func-
tional imaging biomarker (ADC) rather than structural criteria
(RECIST), but also by the use of three-dimensional tumor volume
analysis for the diffusivity measurements. Indeed, because of
tumor heterogeneity, semi-automatic three-dimensional assess-
ment of tumor volume ADC after trans-catheter arterial emboli-
zation has shown better interobserver agreement compared
with manual two-dimensional region of interest measurements
[65].
Besides their usefulness in the assessment of the response to
trans-catheter embolization, ADC measurements are also poten-
tially useful for predicting the response to radioembolization.
One month after treatment of HCC with yttrium-90-labeled
microspheres, increase in tumor ADC was observed, without a
statistically signiﬁcant change in tumor size [66].
Some results about the use of quantitative DW imaging
after antivascular treatments have been reported. After sunitinib694 Journal of Hepatology 201treatment of HCC, perfusion parameters assessed with perfusion
MR imaging might be more sensitive biomarkers in predicting
early response than ADC [67]. After sorafenib treatment of HCC
in another group of patients, it has been reported that changes
of the perfusion fraction f may help differentiating between
responders and non-responders [68].
Few studies report on the potential value of DW MR imaging
for assessing the response of colorectal cancer metastases to
chemotherapy [69,70]. Increase in ADC has been reported after
treatment. It is expected that the changes of the diffusion param-
eters after treatment would be less pronounced in colorectal
metastases than in HCC, because colorectal metastases are less
vascularised and are characterized by ﬁbrosis overgrowth rather
than increase of necrosis after successful chemotherapy [71].
Fibrotic zones within tumors can be differentiated from viable
tumor zones with DW MR imaging by measuring D, the pure dif-
fusion coefﬁcient, but differences in diffusion parameters
between ﬁbrotic and viable zones are less pronounced than
between necrotic and viable zones [72].
Diffuse liver diseases
Progressive decrease of ADC is seen in liver ﬁbrosis, but large
overlaps in ADC measurements between ﬁbrosis stages are
observed [73]. Currently, DW MR imaging alone is not recom-
mended for staging liver ﬁbrosis because its accuracy is not
higher than that of plasma biomarkers measurements and tran-
sient ultrasound elastography, which are more easily-available
methods [73]. Moreover, both animal and human studies have
shown that the decrease of ADC in liver ﬁbrosis may be inﬂu-
enced by other factors than ﬁbrosis. These factors, including
inﬂammation, steatosis and decreased perfusion, may have a
predominant role in ADC decrease [74–76]. Finally, it has been
shown that MR elastography is more accurate than DW MR
imaging to stage liver ﬁbrosis [77].
Dynamic contrast-enhanced MR imaging
Method
Dynamic contrast-enhanced MR imaging is an integral part of
liver MR imaging for the detection and characterization of liver
tumors. At least one image acquisition of the whole liver is
performed during the arterial, portal venous, and delayed phases
(3–5 min after the start of the injection) after bolus injection of
an extracellular gadolinium chelate.
When a hepatocyte-speciﬁc contrast agent is used, such as
gadoxetate (Primovist, Bayer, Berlin, Germany), a hepatobiliary
phase (20 min) is added to the dynamic phase for the assessment
of intracellular retention of the contrast agent. In humans,
gadoxetate is taken up within hepatocytes by the organic anion
transporting polypeptides OATP1 B1/B3. It is excreted into bile
through the multidrug resistance protein MRP2 transporters.
Backﬂow to the sinusoids occurs through MRP3 and the
bidirectional OATP1B1/B3 transporters [4,78,79]. In chronic liver
diseases and HCC, expression and function of the hepatocyte
transporters change, leading to changes of gadoxetate enhance-
ment during the hepatobiliary phase. The transporter changes
consist mainly in decreased OATP1 B1/B3 and MRP2, as well as
increased MRP3 expression [80–82], which causes decreased
lesion signal intensity on gadoxetate-enhanced MR images.
In contrast, some HCC appear hyperintense on gadoxetate-
enhanced MR images during the hepatobiliary phase. Increase5 vol. 62 j 690–700
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Fig. 3. Parametric perfusion and hepatocyte uptake extraction fraction maps.
(A and B) Patient with normal liver, and (C and D) patient with liver cirrhosis,
obtained with dynamic gadoxetate-enhanced MR imaging. Liver perfusion
(ml min1 g1) is more heterogeneous in liver cirrhosis than in normal liver (C
vs. A), and uptake extraction fraction (%) is decreased (D vs. B).
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rather than decrease in OATP1 B3 expression has been found in
these tumors [83].
To perform quantitative perfusion MR imaging, high temporal
resolution at DCE MR imaging is needed, and three-dimensional
MR images of the whole liver should be obtained with a time
resolution <3 s. Simple parameters of lesion enhancement vs.
time curve, such as peak enhancement, time to peak, steepest
slope or area under the enhancement curve are only semi-
quantitative because the shape of the enhancement curve
depends on the shape of the arterial input function. Therefore,
the arterial input function has to be measured in addition to
the tissue enhancement curve, and pharmacokinetic modeling
should be performed to obtain physiological parameters such as
perfusion or extravascular space volume [84].
For liver perfusion assessment, the dynamic curves should be
analyzed with a dual-input model, because the liver has two vas-
cular inputs through the hepatic artery and the portal vein. The
dual-input compartmental model as validated by Materne et al.
is often used [85]. With this model the arterial, portal venous,
and total liver plasma transfer constants K1a, K1p, and K1t, respec-
tively, (ml min1 100 ml1) can be assessed, as well as the
distribution volume vd (%) and the mean transit time MTT (s).
K1 is a lumped representation of perfusion and permeability
(K1 = F  E with F the plasma perfusion and E the extravascular
extraction fraction). When the permeability is high as in the
normal liver, which has sinusoids containing fenestrae with
100 nm diameter, the extraction fraction equals one and K1
represents perfusion. If the permeability is low, K1 approximates
the permeability-surface area product [86]. Because of the large
portal venous input into the liver, hepatic perfusion imaging
should be performed in fasting patients to obtain reproducible
results.
In contrast to the liver parenchyma, primary and secondary
tumors of the liver, except at their early stage, have only an arte-
rial and no portal venous input [87,88]. Therefore, the perfusion
of hepatic tumors, except for early HCC, can be analyzed with sin-
gle input rather than dual-input models. The most used single
input models are the Kety and the extended Kety models. The
Kety model, also called the Tofts model, is a simple dual-com-
partmental model, in which Ktrans (=K1) and the extravascular
extracellular volume (ve = vd) are calculated. In the extended Kety
model, Ktrans, ve, and the plasma volume (vp) are assessed. The
use of more complex distributed-parameter models has been
proposed, but these models are less precise than the compart-
mental models because of the interdependency of the multiple
free parameters and their sensitivity to initial values [89,90].
In perfusion measurements, both the transfer constant Ktrans
and the extravascular extracellular volume ve should be
measured [91]. The reported coefﬁcients of repeatability of Ktrans
in liver tumors are in the range of 20–40% [92]. It has been
reported that ve has a better reproducibility than Ktrans, and ve
measurements allow the assessment of the vascular permeability
by looking at the volume accessible to contrast agents of different
molecular weights [90,93]. Because the reproducibility of the
perfusion measurements depends on the organ, the image
acquisition and data analysis methods, it has been recommended
to assess the reproducibility before starting clinical trials that aim
at assessing treatment response with DCE MR imaging [91].
It should be noted that there is currently no post-processing
standard among the commercially available perfusion analysis
solutions, and this causes large variations in the measuredJournal of Hepatology 201perfusion parameters (reported coefﬁcients of repeatability
>130%) [94]. This variability is mainly explained by the use of dif-
ferent population-based arterial input functions. It underscores
the need for standardizing the perfusion measurements and
using patient-based rather than population-based arterial input
functions. Moreover, the interobserver reproducibility of the
perfusion measurements can be improved with semi-automatic
registration and histogram analysis [95].
With pharmacokinetic analysis of dynamic gadoxetate-
enhanced MR images, liver perfusion and hepatocyte transport
function can be assessed separately using deconvolution or com-
partmental analysis (Fig. 3) [96,97].
Diffuse liver diseases
Dynamic contrast-enhanced MR imaging can be used to assess
the microcirculatory changes in liver ﬁbrosis and cirrhosis.
Decrease of portal and total hepatic perfusion is observed, as well
as increases of arterial perfusion and mean transit time, with pre-
served or increased distribution volume. These perfusion changes
occur already at intermediate stages of liver ﬁbrosis, but are more
marked in cirrhosis, where they correlate with the degree of liver
dysfunction and portal hypertension [86,98]. Decrease of the
hepatobiliary excretion of organic anions through the OATP/
MRP route in liver ﬁbrosis, cirrhosis and non-alcoholic steatohep-
atitis (NASH) can be assessed with gadoxetate-enhanced MR
imaging [82,99–101]. Moreover, gadoxetate-enhanced MR imag-
ing appears promising for the assessment of the risk for liver fail-
ure after major liver resection [102].
Liver tumors
Dynamic contrast-enhanced MR imaging during the arterial, por-
tal venous and delayed phases is routinely performed for tumor
detection, characterization, and assessment of tumor response
to treatment. For these purposes, gadoxetate is increasingly used
rather than extracellular contrast agents. Indeed, numerous
studies have shown that the detection and characterization of
focal liver lesions, including HCC, adenomas, focal nodular
hyperplasias and liver metastases, is improved during the hepa-
tobiliary phase of gadoxetate-enhanced MR imaging [103–105].5 vol. 62 j 690–700 695
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Fig. 4. Multifrequency MR elastography parametric maps of elasticity and
wave dispersion coefﬁcient. Patients with chronic hepatitis C infection classiﬁed
as (A and B) F2 ﬁbrosis, A1 inﬂammation and (C and D) F2 ﬁbrosis, A3
inﬂammation according to METAVIR. Storage modulus values (elasticity in kPa)
are similar in patient with F2, A1 (A) and patient with F2, A3 (C), whereas wave
dispersion coefﬁcients (arbitrary units) are lower in patients with higher
inﬂammation grade (D vs. B). This ﬁgure illustrates the superiority of wave
dispersion coefﬁcient measurements at multifrequency MR elastography relative
to elasticity measurements in discriminating between patients with different
grades of hepatic inﬂammation.
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Particularly, some early hypovascular HCC are only observed as
hypointense nodules during the hepatobiliary phase at gadoxe-
tate-enhanced MR imaging, without being readily seen during
dynamic imaging. The subgroup of lesions showing both absence
of enhancement during the arterial phase and hypointensity dur-
ing the hepatobiliary phase is challenging because not all of these
lesions correspond to HCC or will evolve into HCC [106,107]. In
this setting, hyperintensity on DW MR images increases the like-
lihood of early HCC or progression to hypervascular HCC
[107,108].
In contrast to the qualitative assessment of liver tumors with
DCE MR imaging, quantitative perfusion MR imaging of liver
tumors is not often obtained in clinical practice. The main indica-
tion of perfusion MR imaging is the assessment of tumor
response to antiangiogenic or local treatments [109].
In patients with HCC who received sorafenib plus metronomic
tegafur/uracil therapy, Ktrans measured with DCE-MR imaging
correlated well with tumor response and survival [110]. In
patients with HCC treated with sunitinib, it was found that the
perfusion parameters were more sensitive biomarkers in predict-
ing early response and progression free survival than RECIST and
mRECIST [67]. In another study of HCC treated with sunitinib, it
was observed that the extent of decrease in Ktrans in patients
who experienced partial response or stable disease according to
RECIST was signiﬁcantly greater (twofold on average) compared
with patients with progressive disease or who died during the
ﬁrst two cycles of therapy [111]. Similar results were reported
in patients with potentially resectable metastatic colorectal can-
cer treated with chemotherapy and bevacizumab. In these
patients, progression-free survival beneﬁt was shown for patients
with >40% reduction in Ktrans [112].
Dynamic contrast-enhanced MR imaging and DWMR imaging
may bring complementary predictive information. In patients
with HCC, Bonekamp et al. performed volumetric DCE MR
imaging and DW MR imaging one month after intraarterial
therapy and observed that there were signiﬁcant differences in
overall survival between patients who were dual-parameter
responders (namely patients having decrease in venous enhance-
ment of more than 65% and increase in ADC of more than 25%)
and single-parameter responders, as well as between single-
parameter responders and those with stable disease [64]. These
results show the usefulness of multiparametric functional MR
imaging in the assessment of treatment response.
MR elastography
Method
For MR elastography, external vibrators are used to generate
shear or compression waves. When using compression waves,
the shear waves needed for calculating the visco-elastic parame-
ters are obtained by mode conversion at interfaces within the tis-
sue. The advantage of using compression waves is that they
penetrate within tissues better than shear waves [113]. With
three-dimensional MR elastography, the full visco-elastic proper-
ties of the tissue can be evaluated by measuring shear wave prop-
agation and attenuation. These visco-elastic properties include
the shear modulus G⁄, the storage modulus Gd reﬂecting elastic-
ity, and the loss modulus Gl reﬂecting viscosity. Moreover, with
multifrequency MR elastography, the wave scattering coefﬁcient
corresponding to the slope of the visco-elasticity vs. frequency
curve can be obtained [24,114].696 Journal of Hepatology 201Breathhold MR elastography has a reported repeatability
coefﬁcient of 22% for elasticity and 26% for viscosity in the liver
[115]. The reproducibility of MR elastography for liver ﬁbrosis
has been reported to be better than that of Fibroscan [116].
Diffuse liver diseases
Single center studies have shown that MR elastography is a
robust, reproducible, and accurate method to detect and stage
liver ﬁbrosis [116–119]. MR elastography outperforms transient
ultrasound elastography and aspartate aminotransferase to plate-
lets ratio index (APRI) for hepatic ﬁbrosis staging [116]. In animal
studies, it has been shown that the visco-elastic properties of the
liver correlate with the percentage of hepatic ﬁbrosis determined
at morphometry [120].
As already mentioned, several conditions in addition to ﬁbro-
sis may increase the mechanical properties of the liver, including
inﬂammation, cholestasis, congestion and portal hypertension
[121]. The various visco-elastic parameters determined at multi-
frequency MR elastography may help in disease characterization.
Indeed, studies suggest that liver ﬁbrosis stage mainly correlates
with tissue elasticity, whereas inﬂammation grade mainly
correlates with wave scattering coefﬁcient (Fig. 4) and portal
hypertension degree with liver and spleen viscosity [122–124].
Studies in animals and humans have shown that MR elastog-
raphy may be useful for the early diagnosis of NASH, by showing
early increase in elasticity explained by inﬂammation and
activation of stellate cells [125,126].
If the high diagnostic performance of MR elastography is fur-
ther shown in multicenter trials, it may be particularly relevant
to use this method to complement ultrasound elastography and
avoid liver biopsy in intermediate stages of ﬁbrosis, to stage
portal hypertension and to assess the response to antiﬁbrotic
treatments [27].
Liver tumors
MR elastography may help in the characterization of liver tumors
and the assessment of response to treatment. In a preliminary
study, it has been shown that malignant tumors have a higher5 vol. 62 j 690–700
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stiffness than benign ones [127]. In a more recent study, it has
been observed that malignant liver tumors are mainly character-
ized by increased viscosity [128].
Small animal studies have shown that MR elastography is use-
ful for assessing the early tumor response to vascular disrupting
agents and to chemotherapy [129–131]. Further human trials are
needed to clarify the role of multi-frequency MR elastography in
characterizing liver tumors and assessing their response to
treatment.Conclusions
Ultrasonography and MR imaging of liver diseases evolve from
qualitative anatomical imaging methods to combined quantita-
tive anatomical and functional imaging methods. Imaging bio-
markers obtained with diffusion and perfusion – hepatocyte
transport imaging, as well as with elastography, have an increas-
ing role in the detection and characterization of diffuse liver dis-
eases and liver tumors, and in the assessment of response to
treatment. The multiparametric capability of ultrasonography
and more markedly of MR imaging gives the opportunity of
improved diagnostic performance by combining imaging bio-
markers. For widespread clinical use in liver disease, imaging bio-
markers should be further validated in large multicenter trials.
The image acquisition and post-processing methods should be
further improved and standardized to increase diagnostic accu-
racy and reproducibility.Conﬂict of interest
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